Lowest-Rated StocksLowest-RatedNYSE:NVRO Nevro (NVRO) Stock Price, News & Analysis $9.74 -0.14 (-1.42%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.62▼$10.1450-Day Range$7.61▼$10.5252-Week Range$7.46▼$25.45Volume445,625 shsAverage Volume520,167 shsMarket Capitalization$357.75 millionP/E RatioN/ADividend YieldN/APrice Target$17.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nevro alerts: Email Address Nevro MarketRank™ Stock AnalysisAnalyst RatingReduce1.92 Rating ScoreUpside/Downside81.8% Upside$17.71 Price TargetShort InterestHealthy9.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.14) to ($2.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector538th out of 936 stocksSurgical & Medical Instruments Industry70th out of 101 stocks 4.0 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 1 buy rating, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageNevro has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nevro's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.17% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Nevro has recently decreased by 8.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 1.9 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nevro this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NVRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Nevro to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Nevro is held by insiders.Percentage Held by Institutions95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nevro's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to decrease in the coming year, from ($2.14) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nevro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Nevro Stock (NYSE:NVRO)Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Read More NVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVRO Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Given Consensus Recommendation of "Reduce" by AnalystsJuly 20, 2024 | msn.comMed-tech and healthcare stocks with upside during 2Q earnings - BairdJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 19, 2024 | ca.finance.yahoo.comNVRO Nov 2024 15.000 putJuly 16, 2024 | americanbankingnews.comNevro (NYSE:NVRO) Price Target Lowered to $10.00 at Truist FinancialJuly 16, 2024 | americanbankingnews.comMorgan Stanley Lowers Nevro (NYSE:NVRO) Price Target to $9.00July 11, 2024 | prnewswire.comNevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08July 9, 2024 | prnewswire.comNevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024July 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 28, 2024 | prnewswire.comNevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08June 11, 2024 | prnewswire.comNevro to Present at Truist Securities MedTech ConferenceMay 25, 2024 | finanznachrichten.deNevro Corp.: Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08May 24, 2024 | prnewswire.comNevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08May 23, 2024 | msn.comCitigroup Downgrades Nevro (NVRO)May 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on Nevro Corp (NVRO)May 13, 2024 | markets.businessinsider.comTruist Financial Remains a Hold on Nevro Corp (NVRO)May 10, 2024 | markets.businessinsider.comNevro Corp: Cautious Outlook Amidst Restrained Growth and Strategic EffortsMay 10, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Nevro Corp. (NYSE:NVRO) Price Target To US$15.30See More Headlines Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,215Year FoundedN/APrice Target and Rating Average Stock Price Target$17.71 High Stock Price Target$40.00 Low Stock Price Target$8.20 Potential Upside/Downside+81.8%Consensus RatingReduce Rating Score (0-4)1.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,210,000.00 Net Margins-19.17% Pretax Margin-20.47% Return on Equity-27.48% Return on Assets-13.40% Debt Debt-to-Equity Ratio0.77 Current Ratio7.38 Quick Ratio5.57 Sales & Book Value Annual Sales$425.17 million Price / Sales0.84 Cash FlowN/A Price / Cash FlowN/A Book Value$8.10 per share Price / Book1.20Miscellaneous Outstanding Shares36,730,000Free Float35,554,000Market Cap$357.75 million OptionableOptionable Beta0.91 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Kevin R. Thornal (Age 50)President, CEO & Director Comp: $1.37MMr. Roderick H. MacLeod (Age 57)Senior VP & CFO Comp: $653.1kMr. Kashif Rashid (Age 50)Senior VP of Corporate Development & Chief Legal Officer Comp: $629.62kMr. Greg Siller (Age 43)Senior VP & Chief Commercial Officer Comp: $419.9kMr. Richard B. Carter (Age 53)Chief Accounting Officer Mr. Christofer Christoforou (Age 54)Senior Vice President of Technical Operations Comp: $367.4kGeeta KavetiVP and Chief Compliance & Privacy OfficerMeredith VornholtVice President of Global MarketingMs. Shana D. Ross M.B.A. (Age 51)Senior VP & Chief Human Resources Officer Dr. David Caraway M.D. (Age 67)Ph.D., Senior VP & Chief Medical Officer More ExecutivesKey CompetitorsAtriCureNASDAQ:ATRCArtivionNYSE:AORTSilk Road MedicalNASDAQ:SILKMiMedx GroupNASDAQ:MDXGPulse BiosciencesNASDAQ:PLSEView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 8,673 shares on 7/26/2024Ownership: 0.348%Nisa Investment Advisors LLCBought 6,565 shares on 7/20/2024Ownership: 0.019%Assenagon Asset Management S.A.Bought 605,134 shares on 7/18/2024Ownership: 1.983%California State Teachers Retirement SystemSold 5,051 shares on 5/16/2024Ownership: 0.090%Price T Rowe Associates Inc. MDBought 7,004 shares on 5/15/2024Ownership: 0.123%View All Institutional Transactions NVRO Stock Analysis - Frequently Asked Questions How have NVRO shares performed this year? Nevro's stock was trading at $21.52 at the beginning of 2024. Since then, NVRO stock has decreased by 54.7% and is now trading at $9.74. View the best growth stocks for 2024 here. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) issued its earnings results on Tuesday, May, 7th. The medical equipment provider reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.02) by $0.32. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. Who are Nevro's major shareholders? Top institutional shareholders of Nevro include Assenagon Asset Management S.A. (1.98%), Bank of New York Mellon Corp (0.35%) and Nisa Investment Advisors LLC (0.02%). Insiders that own company stock include Kashif Rashid, Shawn Mccormick, D Keith Grossman, Elizabeth H Weatherman and Kevin C Oboyle. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU) and Gilead Sciences (GILD). This page (NYSE:NVRO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nevro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
